The acquisition of Advanced Patient Monitoring is a key driver of revenue growth, particularly in the Medical segment. The company is integrating Advanced Patient Monitoring into its operations and expects synergies.

On February 5, 2025, BD announced its intention to separate its Biosciences and Diagnostic Solutions businesses. The company expects to announce more specifics on the separation plans by the end of fiscal year 2025 and intends to target completion of the transaction in fiscal year 2026.

BD is investing in research and development, strategic tuck-in acquisitions, geographic expansion, and new product programs to drive further revenue and profit growth. This is part of their BD 2025 strategy for growth.

The company is experiencing temporary shortages in supply of certain materials and components. They expect an estimated impact of $90 million from tariffs to fiscal year 2025 operating expense.

The company incurred restructuring costs related to simplification and other cost-saving initiatives. These initiatives are focused on reducing complexity, optimizing the Company's supply chain efficiency and improving cost efficiency across all of the Company's segments.

The company is working to remediate issues related to the FDA consent decree for its infusion pumps. BD received 510(k) clearance from the FDA for its updated BD Alaris Infusion System, which enables both remediation and a return to market for the BD Alaris Infusion System.

The company's international operations are subject to changing political, social, and geopolitical conditions, such as the evolving situations in Ukraine, the Middle East and Asia. These conditions include instability resulting from war, terrorism, insurrections and civil unrest, political conflict, and changing economic conditions.

The company faces risks related to product efficacy or safety concerns, changes to the labeled use of our products, and non-compliance with applicable regulatory requirements regarding our products. This can result in product recalls, lost revenue or other actions being taken with respect to products in the field.

There is increased focus on the use and emission of ethylene oxide by the U.S. Environmental Protection Agency and state environmental regulatory agencies. This could result in additional regulatory requirements and litigation.

Competitive factors that could adversely affect the company's operations include new product introductions and technologies, including the use of artificial intelligence, by current or future competitors, consolidation or strategic alliances among healthcare companies, distributors and/or payers of healthcare.

Cost-containment efforts in the U.S. or in other countries in which the company does business, such as alternative payment reform, government-imposed pay back provisions, increased use of competitive bidding and tenders, could affect the company's pricing and demand.

The company monitors and adapts to changes in the way healthcare services are delivered, including transition of more care from acute to non-acute settings and increased focus on chronic disease management, which may affect the demand for our products and services.

The company is focused on optimizing the Company's supply chain efficiency, streamlining its global manufacturing footprint, enhancing product quality, refining customer experience, and improving cost efficiency across all of the Company's segments.

The company is experiencing temporary shortages in supply of certain materials and components. They expect an estimated impact of $90 million from tariffs to fiscal year 2025 operating expense.

The company is working to remediate issues related to the FDA consent decree for its infusion pumps. BD received 510(k) clearance from the FDA for its updated BD Alaris Infusion System, which enables both remediation and a return to market for the BD Alaris Infusion System.

BD is investing in research and development to drive further revenue and profit growth. This is part of their BD 2025 strategy for growth.

Our ability to sustain our long-term growth will depend on a number of factors, including our ability to expand our core business, and develop innovative new products, as well as continue to improve operating efficiency and organizational effectiveness.

Difficulties inherent in product development, including the potential inability to successfully continue technological innovation, successfully complete clinical trials, obtain and maintain regulatory approvals and registrations in the U.S. and abroad, obtain intellectual property protection for our products.

During the first six months of fiscal year 2025, the company paid cash dividends to common shareholders of $600 million.

The company repurchased 620,691 shares of common stock during the quarter ended March 31, 2025, including shares received upon final settlement of a $750 million accelerated share repurchase (ASR) agreement.

The company funded the Advanced Patient Monitoring acquisition with cash on hand, using net proceeds raised through debt issuances in the third quarter of fiscal year 2024 and borrowings under its commercial paper program.

The impact of climate change, or legal, regulatory or market measures to address climate change, such as regulation of greenhouse gas emissions, zero-carbon energy and sustainability mandates and related disclosure requirements, and additional taxes on fuel and energy.

Companies generally have two years from the effective date to comply with the new requirements of the NESHAP. We are in the process of implementing certain changes to our facilities in accordance with NESHAP's requirements.

We are assessing the impact of the ID on our sterilization facilities, on the third-party sterilization facilities that BD utilizes and on our operations more generally.

The company monitors and adapts to changes in the way healthcare services are delivered, including transition of more care from acute to non-acute settings and increased focus on chronic disease management, which may affect the demand for our products and services.

General global, regional or national economic downturns and macroeconomic trends, including heightened inflation, capital market volatility, including volatility resulting from the imposition of and changing policies around tariffs, import or export licensing requirements, other governmental restrictions such as trade sanctions.

Conditions in international markets, including social and political conditions, geopolitical developments such as the continuation and/or escalation of the evolving situations in Ukraine, the Middle East and Asia, civil unrest, political conflict, terrorist activity, governmental changes.